Changes to This Summary (01/27/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Göbel et al. as reference 14.
Added text to state that patients with a malignant mediastinal primary tumor and extracranial metastases are at the highest risk of developing brain metastases and are followed closely for signs and symptoms of central nervous system involvement (cited Göbel et al. as reference 19 and level of evidence 3iiB).
Added text to state that a single-institution study of 44 young people with refractory or recurrent extracranial GCTs, using cisplatin/etoposide/ifosfamide and regional deep hyperthermia with or without surgery plus radiation therapy for residual tumor, showed a response rate of 86% in 35 patients who had sufficient data available; the 5-year event-free survival was 62% and the 5-year overall survival was 72%. However, regional hyperthermia facilities are limited and not readily available for children in the United States. Further study is needed in children and adolescents (cited Wessalowski et al. as reference 24 and level of evidence 3iiDi).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.